CN106309360A - Preparation method of long-acting hydrochloric ceftiofur injection - Google Patents
Preparation method of long-acting hydrochloric ceftiofur injection Download PDFInfo
- Publication number
- CN106309360A CN106309360A CN201610822133.6A CN201610822133A CN106309360A CN 106309360 A CN106309360 A CN 106309360A CN 201610822133 A CN201610822133 A CN 201610822133A CN 106309360 A CN106309360 A CN 106309360A
- Authority
- CN
- China
- Prior art keywords
- grinding
- ceftiofur
- preparation
- content
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method of a long-acting hydrochloric ceftiofur injection. The preparation method is characterized by including: using soybean oil as a solvent, heating the soybean oil to 140-150 DEG C, holding the temperature for 60min for sterilizing, and cooling to room temperature; dissolving or dispersing 0.5-2.0wt% of and 0.5-1.5wt% of according to prescription amounts in 70-80% of the sterilized solvent; guiding into a colloid mill for grinding, adding 10.2-10.8wt% of hydrochloric ceftiofur according to a prescription amount after grinding is finished, adopting a mode of alternating circulating grinding and non-circulating grinding for grinding, checking whether particle fineness reaches 2.5-5.0um or not, stopping grinding after requirements are met, and adding the sterilized solvent to the prescription amount to obtain an intermediate product; testing ceftiofur content and product character of the intermediate product, after passing needle drawing experiment, filling, externally packing, warehousing, and obtaining the injection after passing tests of content, sterility, granularity and related matter. Results show that when consumption of and is 1%, production process and product quality of the injection are stable.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, in particular it relates to the preparation side of a kind of long-acting ceftiofur hydrochloride injection
Method.
Background technology
Ceftiofur (Ceftiofur) has another name called ceftiofur, is by Bernard Labeeuw et al. in 1984 first the earliest
Synthesis, is the special Third generation Cephalosporins antibiotic of first poultry；Thereafter Pharmacia-Pu Qiang company
(Pharmacia&Upjohn) made the lyophilized powder of sodium salt and hydrochlorate suspension (trade name Naxcel,
Excenel) for the treatment of Animal diseases.
Ceftiofur absorbs rapidly, and bioavailability is high；High with vivo protein matter combination rate, form stock's sterilizing power, half
Phase of declining is long, lasting medicine；Compared with other antibiotic, this medicine be unique in that medicine content ratio in infected tissue is non-
In infected tissue high 2～4 times, in there being the integrated distribution of target, play bactericidal action.
Ceftiofur mainly kills antibacterial by acting on the synthesis of transpeptidase blocking-up bacteria cell wall；To various leather orchids
Family name's positive bacteria (such as staphylococcus), gram negative bacteria (such as escherichia coli, Salmonella, bacillus pyocyaneus) and some anaerobe are all
There is the strongest antibacterial activity.Ceftiofur residual in tissue is low, and safety is good, molecular structure stabilized and will not be by beta-lactam
Enzyme destroys, and is not likely to produce drug resistance and cross resistance, is the antibiotic that sterilizing power the most for animals is the strongest, has at present
The multiple superiority that other antibiotic of veterinary drug market popularity is incomparable.
The preparation of China's approval at present has ceftiofur soluble powder and suspension injection, and these products are treatment animal
Disease has played due effect.Yet with the effective blood drug concentration of above-mentioned preparation hold time mostly 24-32 hour it
Between, need inject every day during clinical treatment, make troubles to the treatment work of veterinary, also result in the discomfort for the treatment of animal simultaneously
Ying Xing.
A kind of long-acting ceftiofur hydrochloride injection and preparation method thereof (Chinese patent application is applicant has invented for this
Numbers 200910050126.9), it is formed by the preparation of raw material of following percentage by weight: 10.2%～10.8% hydrochloric acid cephalo thiophene
Furan, 2.0～6.5% pharmaceutic adjuvant, surplus are injection soybean oil.Additives include lecithin, span-80 and propylene glycol.Ovum
Content of phospholipid is 0.5～2.0%, preferably 1.0%.Span-80 content is 0.5～1.5%, preferably 1.0%.Propylene glycol contains
Amount is 1.0～3.0%, preferably 2.0%.This long-acting ceftiofur hydrochloride injection, its preparation method is the injection with heating
Additives are dissolved with soybean oil, sterilizing after stirring and evenly mixing, add Ceftiofur Hydrochloride after cooling, use homogenizer mixing all
Even, aseptic subpackaged obtain injection finished product.
This long-acting ceftiofur hydrochloride injection can slowly discharge drug effect, Blood drug concentration hold time 72 hours with
On, it is much higher than existing Ceftiofur Hydrochloride injecta, is once reduced to injection one in 3 days by injecting the every day of regular dosage form
Secondary, and good stability.The preparation method of this long-acting ceftiofur hydrochloride injection is simple, uses high-shear homogenizing machine to carry out even
Slurry operation, obtains 10-15 μm Nanoparticle medicinal liquid, decreases the medicinal liquid zest to injection site.
But this long-acting ceftiofur hydrochloride injection tablets in vitro test T50%Only 3.8h, after the accelerated test of 6 months
Ceftiofur content is only the 92.5～93.3% of former content.
Summary of the invention
The technical problem to be solved is for disclosed in Chinese Patent Application No. 200910050126.9
Problem that a kind of long-acting ceftiofur hydrochloride injection and preparation method thereof is existing and a kind of long-acting ceftiofur hydrochloride is provided
The preparation method of injection.Long-acting ceftiofur hydrochloride injection prepared by this preparation method is ensureing suspension sedimentation slowly,
While being prone to the characteristic of redispersion, tablets in vitro T50%And the stable content after 6 months accelerated tests is significantly increased.
The technical problem to be solved can be achieved through the following technical solutions:
The preparation method of a kind of long-acting ceftiofur hydrochloride long-acting injection: with soybean oil as solvent, first soybean oil is added
Heat to 140～150 DEG C and is cooled to room temperature after being incubated sterilizing in 60 minutes；Take the lecithin and 0.5 of recipe quantity 0.5～2.0wt%
～the span-80 of 1.5wt% is dissolved or dispersed in the sterile vehicle of 70%～80%, it is then introduced into colloid mill and is ground,
Add 10.2%～10.8wt% Ceftiofur Hydrochloride of recipe quantity after grinding, then use circular grinding and acyclic grind
Mill mode alternately is ground, and checks that fineness of the particles reaches 2.5-5.0 μm, stops grinding, add sterile vehicle after meeting the requirements
Both intermediate products had been obtained to formula ratio；Take intermediate products inspection ceftiofur content, product characteristics and consistence test qualified after, fill
Dress, outsourcing, ware-house-in inspection content, aseptic, granularity, after having related substance qualified and get final product.
In a preferred embodiment of the invention, described lecithin content is 1%, and span-80 content is 1%.
Owing to have employed technical scheme as above, use long-acting ceftiofur hydrochloride injection body prepared by the inventive method
Outer Drug Releasing Test T50%Reaching 5.2h, after the accelerated test of 6 months, ceftiofur content is the 98.8% of former content.
Detailed description of the invention
1. instrument and reagent
Colloid mill (Shanghai Dong Hua high pressure homogenizer factory)；A gillent 1100 high performance liquid chromatograph；AG285 type electronics
Analytical balance (Mei Teletuo benefit Instrument Ltd. of Switzerland)；Ceftiofur reference substance (China Veterinery Drug Inspection Office, batch
Number: K0330702)；Span-80 (Shanghai Shen Yu medication chemistry company limited)；Lecithin (the Shanghai limited public affairs of Ai Kang fine chemistry industry
Department)；Injection soybean oil (Tian Yu Camellia oil development corporation, Ltd.).
2. method and result
2.1 prescriptions and technique
2.1.1 prescription composition
Ceftiofur Hydrochloride 5kg, span-80 (wetting agent) 0.5L, lecithin (suspending agent) 0.5L, injection soybean oil
(solvent) adds to 50L.
2.1.2 technical process
Production process prepared, filter, all open surfaces contacted with medicinal liquid such as pipeline, process by the following method: join
1%NaOH solution processed → wash or steep 5min → water for injection and clean to neutral, then dry up with nitrogen.
With soybean oil as solvent, after first soybean oil being heated to 140～150 DEG C and being incubated sterilizing in 60 minutes, it is cooled to room
Temperature.The suspending agent and the wetting agent that take recipe quantity are dissolved or dispersed in the sterile vehicle of 70%～80%, are then introduced into colloid mill
It is ground, adds the Ceftiofur Hydrochloride of recipe quantity after grinding, then use circular grinding and acyclic grinding alternately
Mode be ground, check fineness of the particles reach 2.5-5.0 μm, after meeting the requirements stop grind, add sterile vehicle to formula
Amount had both obtained intermediate products；Take intermediate products inspection ceftiofur content, product characteristics and consistence test qualified after, fill, outsourcing,
Ware-house-in inspection content, aseptic, granularity, after having related substance qualified and get final product.
2.2 technical study
By adding span-80 (v/v) and the difference of lecithin (v/v), operate with method, use the body of dialysis detection product
Outer release situation and stability.
2.2.1 tablets in vitro experiment
Precision measures the sample formulation of different formulations, puts in bag filter, and two ends are tightened, with the Ammoniom-Acetate of 0.05mol/L:
Acetonitrile (80: 20v/v) is release medium, stirs with the speed of 100rpm, dialyses, not in the case of 37.5 DEG C of heated at constant temperature
Discharge liquid with drawing 0.4ml at time point, supplement commensurability release medium simultaneously.Use the cephalo in HPLC detection release medium
Thiophene furan concentration, investigates the vitro release of sample.
2.2.2 accelerated stability test
The durative action preparation sample of different formulations is respectively placed under 40 ± 2 DEG C of water bath condition after measuring content the same day, makees
Sampled after 6 months.Use HPLC detection level, observe the color change of preparation simultaneously.
2.2.3 result
By span-80 and the different amounts of lecithin, adopt and prepare sample with the aforedescribed process.The release in vitro situation of sample
And stability result is shown in Table 1.Visible, when the consumption of wetting agent span-80 be 1%, the consumption of suspending agent lecithin be 1% time,
This sample has preferable slow releasing function and more stable.
The formula of table 1 span-80 and lecithin investigates result
By Span-8 and the different amounts of lecithin, according to disclosed in Chinese Patent Application No. 200910050126.9
The preparation method planting long-acting ceftiofur hydrochloride injection prepares comparative sample.The release in vitro situation of comparative sample and stability
The results are shown in Table 2.Visible, when the consumption of wetting agent span-80 be 1%, the consumption of suspending agent lecithin be 1% time, this control sample
The slow releasing function of product is worse than the present invention, and stability is also worse than the present invention.
The formula of table 2 span-80 and lecithin investigates result
3. discuss
Ceftiofur Hydrochloride is crystalline powder, readily soluble in water, insoluble in oil phase.Ceftiofur Hydrochloride is in oil phase
Dispersion suspendible, suspending agent need to be used to increase suspension dynamic stability.Suspending agent is that a class has sticking hydrophilic gel
Body material, application suspending agent can increase the dispersion viscosity of matchmaker, the sedimentation velocity of the microgranule that slows down, and can be adsorbed on microparticle surfaces
For stoping the barrier of particles agglomerate caking.The most also needing to apply wetting agent to make the material can be dispersed in oil, wetting agent be permissible
Make that dispersion phase dispersion is big, good stability, be susceptible to extraneous factor impact.Not phase inversion when disperse phase concentration increases, not by micro-life
The decomposition of thing and destruction, keep having enough electrostatic repulsions between different undissolved material, it is therefore prevented that each other simultaneously
Collision rift produces polymerization, so that suspensoid produces preferable dispersion effect.
Principal agent discriminating, content etc. are produced the size of impact, sinking in combination with suspension by experimentation according to adjuvant
Adjuvant is screened by the fall parameter request such as volume ratio, redispersibility, determines prescription further according to stability test data.By examining
Examine the different suspending agent single-factor influence to long-acting ceftiofur hydrochloride injection, determine that employing lecithin is as suspending agent.?
On the basis of this, then investigate different wetting agent suspension affected situation, according to pertinent literature report and trial test result, select
Determine span-80 as wetting agent.The span-80 of different amounts and lecithin are investigated to product release and stability
Impact, result shows, when the consumption of span-80 and lecithin is 1%, the production technology of Ceftiofur Hydrochloride injecta and product
Quality is more stable.
Claims (2)
1. a preparation method for long-acting ceftiofur hydrochloride injection, is characterized in that with soybean oil as solvent, first by soybean oil
It is cooled to room temperature after being heated to 140～150 DEG C and being incubated sterilizing in 60 minutes；Take recipe quantity 0.5～2.0wt% lecithin and
The span-80 of 0.5～1.5wt% is dissolved or dispersed in the sterile vehicle of 70%～80%, is then introduced into colloid mill and grinds
Mill, adds 10.2%～10.8wt% Ceftiofur Hydrochloride of recipe quantity after grinding, then use circular grinding and non-follow
Ring grinds mode alternately and is ground, and checks that fineness of the particles reaches 2.5-5.0 μm, stops grinding, add sterilizing after meeting the requirements
Solvent had both obtained intermediate products to formula ratio；Take intermediate products inspection ceftiofur content, product characteristics and consistence test qualified after,
Fill, outsourcing, ware-house-in inspection content, aseptic, granularity, after having related substance qualified and get final product.
The preparation method of a kind of long-acting ceftiofur hydrochloride injection the most as claimed in claim 1, is characterized in that, described ovum phosphorus
Fat content is 1%, and span-80 content is 1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610822133.6A CN106309360B (en) | 2016-09-13 | 2016-09-13 | A kind of preparation method of long-acting ceftiofur hydrochloride injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610822133.6A CN106309360B (en) | 2016-09-13 | 2016-09-13 | A kind of preparation method of long-acting ceftiofur hydrochloride injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106309360A true CN106309360A (en) | 2017-01-11 |
| CN106309360B CN106309360B (en) | 2018-08-10 |
Family
ID=57787766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610822133.6A Active CN106309360B (en) | 2016-09-13 | 2016-09-13 | A kind of preparation method of long-acting ceftiofur hydrochloride injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309360B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112924633A (en) * | 2021-05-10 | 2021-06-08 | 天津瑞普生物技术股份有限公司 | Sterility detection method for ceftiofur oil suspension injection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406447A (en) * | 2007-10-12 | 2009-04-15 | 河南农业大学 | Technique for preparing compound ceftiofur oil suspension injection |
| CN101874773A (en) * | 2009-04-28 | 2010-11-03 | 上海市动物疫病预防控制中心 | Long-acting ceftiofur hydrochloride injection and preparation method thereof |
| CN102018669A (en) * | 2010-11-19 | 2011-04-20 | 武汉回盛生物科技有限公司 | Long-acting ceftiofur hydrochloride injection and preparation method thereof |
-
2016
- 2016-09-13 CN CN201610822133.6A patent/CN106309360B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406447A (en) * | 2007-10-12 | 2009-04-15 | 河南农业大学 | Technique for preparing compound ceftiofur oil suspension injection |
| CN101874773A (en) * | 2009-04-28 | 2010-11-03 | 上海市动物疫病预防控制中心 | Long-acting ceftiofur hydrochloride injection and preparation method thereof |
| CN102018669A (en) * | 2010-11-19 | 2011-04-20 | 武汉回盛生物科技有限公司 | Long-acting ceftiofur hydrochloride injection and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| "《中药药剂学》" * |
| 司红彬等: "头孢噻呋混悬注射液的研制及疗效试验", 《河南农业大学学报》 * |
| 张文刚等: "长效盐酸头孢噻呋注射液的生产工艺研究", 《上海畜牧兽医通讯》 * |
| 贾艳华等: "兽用抗菌药缓释注射剂研究", 《兽医导刊》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112924633A (en) * | 2021-05-10 | 2021-06-08 | 天津瑞普生物技术股份有限公司 | Sterility detection method for ceftiofur oil suspension injection |
| CN112924633B (en) * | 2021-05-10 | 2021-08-10 | 天津瑞普生物技术股份有限公司 | Sterility detection method for ceftiofur oil suspension injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106309360B (en) | 2018-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176617B (en) | Amoxicillin soluble powder and preparation method thereof | |
| CN102988291B (en) | Flurbiprofen axetil fat emulsion injection composition and preparation method thereof | |
| JPH06510772A (en) | Pharmaceutical carrier made of solid lipid microparticles (solid lipid nanospheres) | |
| CN106137973A (en) | A kind of compound sulfonamide chloropyrazine soluble powder of sodium and preparation method thereof | |
| CN104546703B (en) | A kind of Lactation of Dairy Cow phase is with Cefquinome sulfate breast injection and preparation method thereof | |
| CN106074543A (en) | A kind of water solublity synergistic composition containing amoxicillin and application thereof | |
| CN107595782A (en) | A kind of Linezolid dry suspensoid agent and preparation method thereof | |
| CN106309360B (en) | A kind of preparation method of long-acting ceftiofur hydrochloride injection | |
| US11612566B2 (en) | Lamotrigine oral liquid suspension and use thereof | |
| CN104013629B (en) | The compound medicament composition of cefoperazone sodium and tazobactam sodium and preparation technology thereof | |
| CN106265506A (en) | A kind of amoxicillin colistine sulfate oil suspension and preparation method thereof | |
| CN105853351A (en) | Linezolid oral suspension and preparation method theroef | |
| CN101945670A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| CN104688713A (en) | Cefradine capsule and preparation method thereof | |
| CN103191058A (en) | Aqueous suspension injection of cephalosporin medicines, and preparation method thereof | |
| CN102335136B (en) | Meropenem medicinal composition for injection and preparation method thereof | |
| CN101874773B (en) | Long-acting ceftiofur hydrochloride injection and preparation method thereof | |
| CN102397282A (en) | Long-acting compound ceftiofur suspension injection and its preparation method | |
| CN106265505B (en) | A kind of amoxicillin and clavulanate potassium oil suspension and preparation method thereof | |
| CN105769874B (en) | Animal use suspensoid liquid and preparation method thereof containing Ceftiofur and baicalein | |
| CN102335137B (en) | Medicinal composition containing meropenem | |
| CN103432076A (en) | Cefprozil dry suspension and preparation method thereof | |
| CN102988305B (en) | Medicinal composition containing meglumine cyclic adenosine monophosphate compound | |
| CN103211827B (en) | Compound amoxicillin oil suspension prescription and preparation method thereof | |
| CN103705514A (en) | Composition containing nimodipine, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |